Tata Consultancy Services: IT major Tata Consultancy Services (TCS) on Thursday reported a profit after tax (PAT) of Rs 6,603 crore for the September quarter. This was 4.51 per cent QoQ higher than June quarter PAT of Rs 6318 crore the firm reported in June quarter.
Infosys: The second largest domestic IT firm, Infosys, is likely to see a 3 per cent sequential growth in September quarter revenues in constant currency terms, while it is seen cutting its FY17 revenue guidance for second time this year to 8-9.5 per cent against 10.5-12 per cent forecast earlier.
Reliance Industrial Infrastructure Ltd: RIIL reported 19 per cent decline in net profit to Rs 3.38 crore for the quarter ended September 30, 2016. The company had posted a net profit of Rs 4.19 crore in the year-ago period, RIIL said in a filing to BSE.
ONGC: Oil & Natural Gas Corp., the largest Indian oilBSE 1.06 % and gas explorer, and Hong Kong-listed United Energy Group Ltd. are among bidders for Bangladesh natural gas assets being sold by Chevron Corp., said a media report quoting people with knowledge of the matter.
Cox & Kings: Cox & Kings-owned Meininger Hotels has signed an agreement with Beni Stabili SIIQ to set up a 491-bed hotel in Milan, Italy.
ICICI Bank: ICICI Bank, India’s largest private sector lender, has hit the capital markets, raising Rs 4,000 crore in a bond issue amid hopes of better credit growth during the busy season from October to March.
NHPC : State-run NHPC has got shareholders’ nod to raise up to Rs 4,500 crore through issuance of bonds on private placement basis in domestic market in the next one year.
GNFC: Toluene diisocyanate – TDI – prices have increased sharply over the past few days , a huge positive for Gujarat National Fertilizer Company (GNFC), a Gujarat state-owned fertilizer and chemical company and the only manufacturer of TDI in India.
Karnataka Bank Ltd: The bank has fixed October 25 as record date for the purpose of determining the shareholders eligible to apply for rights equity shares.
Lupin : German drug giant Boehringer Ingelheim has entered into an agreement with Mumbai-based Lupin to co-market empagliflozin, a novel drug for the treatment of Type-II diabetes in adults.